GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (STU:CF5) » Definitions » Profitability Rank

Can Fite Biofarma (STU:CF5) Profitability Rank : 1 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Can Fite Biofarma Profitability Rank?

Can Fite Biofarma has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Can Fite Biofarma's Operating Margin % for the quarter that ended in Dec. 2023 was -1,184.51%. As of today, Can Fite Biofarma's Piotroski F-Score is 2.


Competitive Comparison of Can Fite Biofarma's Profitability Rank

For the Biotechnology subindustry, Can Fite Biofarma's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Profitability Rank falls into.



Can Fite Biofarma Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Can Fite Biofarma has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Can Fite Biofarma's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-1.682 / 0.142
=-1,184.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Can Fite Biofarma has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Can Fite Biofarma Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -42.1%.

4. Consistency of the profitability

5. Predictability Rank


Can Fite Biofarma Profitability Rank Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (STU:CF5) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (STU:CF5) Headlines

No Headlines